Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

EGFR-mutant Non-small Cell Lung Cancer × naporafenib × 1 year × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Melanoma 4 Colorectal Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Thyroid Neoplasms 1 Rectal Neoplasms 1 Pancreatic Neoplasms 1 Neoplasm Metastasis 1 Lung Neoplasms 1 EGFR-mutant Non-small Cell Lung Cancer 1 Colonic Neoplasms 1 Adenocarcinoma of Lung 1

Interventions

trametinib 1 ribociclib 1 nazartinib 1 naporafenib 1 capmatinib 1 Gefitinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03333343 2026-01-16

Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC

Novartis

Phase 1 Active not recruiting

EGFR-mutant Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡